跳转到内容

ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study

SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced positive efficacy results in its phase 2 inpatient chronic spontaneous urticaria study with neffy (epinephrine nasal spray), an investigational new drug. The trial met its primary endpoints with both 1 mg and 2 mg neffy demonstrating statistically significant and clinically meaningful changes from baseline in itch, hives, urticaria and erythema scores as early as 5 minutes after dosing. Urticaria is a skin disorder that causes itchy hives and/or angioedema; 50% of chronic urticaria cases1 are non-responsive to first-line antihistamine therapy. ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study

Verteidigung: EMP-Waffen können USA zerstören

Eine einzige Nuklearexplosion genügt, um die Vereinigten Staaten lahmzulegen – und die Bevölkerung ins Mittelalter zu katapultieren. Das zeigt Steven Starr in seinem neu erschienenen Buch “Nuclear High-Altitude Electromagnetic Pulse”. US gegen EMP-Waffen machtlos Das Stromnetz des Landes würde ebenso zerstört wie das gesamte Kommunikationssystem, die Kühlsysteme der Kernkraftwerke und alle elektronischen Geräte. Der Grund dafür… Verteidigung: EMP-Waffen können USA zerstören

man holding laptop computer with both hands

Lab Cybersicherheit: White Hause empfiehlt Python

Labore und medizinische Einrichtungen sollten ihre IT-Strategie überdenken: Das US-amerikanische Office of the National Cyber Director (ONCD) des Weißen Hauses hat am gestrigen Montag einen Bericht veröffentlicht, der speichersichere Programmiersprachen wir beispielsweise Python empfiehlt.

City of Hope scientists destroy leukemia stem cells

Scientists at City of Hope, one of the largest cancer research and treatment organizations in the United States, have devised an innovative approach to target and destroy hard-to-kill leukemia stem cells. The journal Blood published the preclinical findings today. By overcoming challenges, such as drug resistance and treatment relapse common to patients with acute myeloid leukemia (AML), the therapy method could provide a less toxic and more effective approach for older and sicker patients who don’t quality for stem cell transplants — currently the only cure for AML available. Type II interferon (IFNy), a substance produced by immune cells, disrupts the leukemia stem cells’ ability to divide and spread cancer. However, IFNy also stimulates CD38, a protein that suppresses the immune cells’ ability to mount a response against infection. To overcome this challenge, the researchers designed a T cell engager… 

more »City of Hope scientists destroy leukemia stem cells
LabNews by Corax Consultants LLC copyright Corax Consultants LLC

全球经济活动保持低迷

华盛顿，2月26日/LabNews。全球经济增长和经济活动的গুলির中期前景仍然黯淡。这是国际货币基金组织（IMF）的最新报告，该报告在2月28日至29日于巴西圣保罗举行的G20财政部长和中央银行行长会议之前发布。“世界经济似乎正走上软着陆的道路，但活动和增长前景仍然疲软，”报告称。“中期增长前景仍然低迷——这反映了长期的趋势和挑战，包括生产力增长缓慢、人口老龄化、地缘经济碎片化和气候脆弱性。这些趋势也削弱了收入趋同，并增加了经济体抵御外部冲击的脆弱性，”IMF专家补充道。

Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has accepted an offer from investors (the “Investors”) for the sale of 10,127,132 of its ordinary shares, for an approximate value of USD 166 million, par value USD 0.01 per share (the “Shares”), at a purchase price of USD 16.41 per Share, or ISK 2,250 per share at foreign exchange rates on February 23, 2024 (the “Transaction”). The Shares are expected to be delivered to the Investors from previously issued treasury shares held by Alvotech’s subsidiary, Alvotech Manco ehf. The Transaction will be made on the Nasdaq Iceland Exchange. Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share

Foto Credits Courtesy of DiaSorin

Universelles Neugeborenen-Screening auf kongenitale CMV gefordert

Es sei an der Zeit, dass die US-amerikanischen klinischen Laboratorien den Test auf Cytomegalie-Viren (CMV) als Teil des Standard-Screenings für Neugeborene etablieren. Das fordert Michelle Tabb, Chief Scientific Officer beim US-Molekulardiagnostik Spezialisten Diasorin.